Leon Bernal-Mizrachi, MD, of Emory University, Atlanta, GA, discusses a study aiming to characterize whether NFκB2 gene rearrangement can predict response to ixazomib in multiple myeloma. This Phase II trial tests ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFκB2 rearrangement (NCT02765854). This interview took place at the international myeloma workshop (IMW) 2019, in Boston, MA.